Epigenetics Market Projected to Garner $1,321 Mn by 2023 at 13.1% CAGR, Says AMR

PORTLAND, Oregon, Feb. 20, 2019 /PRNewswire/ -- Allied Market Research published a report, titled, "Epigenetics Market by Product [Enzymes (DNA Ligases, DNA Polymerases, Other DNA-modifying Enzymes), Kits & Assays (Bisulfite Conversion Kits, Chip-Seq Kits, Deep Sequencing Kits, Methyltransferase Assays, Histone Assays, Immunoprecipitation Kits), Instruments (Mass Spectrometers, Next-generation Sequencers, qPCRs, and Sonicators), and Reagents (Antibodies, Buffers, Histones, Magnetic Beads, Primers, and Other Epigenetics Reagents)], Application (Oncology and Non-oncology Diseases, Developmental Biology, Drug Discovery, and Others), and End User [Academic & Research Institutes, Pharmaceutical Companies, Biotechnology Companies, and Contract Research Organizations (CROs)] - Global Opportunity Analysis and Industry Forecast, 2017-2023. According to the report, the global epigenetics market was valued at $630 million in 2017 and is expected to reach $1,321 million by 2023, registering a CAGR of 13.1% during the forecast period.

The surge in prevalence of cancer and other infectious diseases, increase in genome mapping programs worldwide, and advancements in gene technology drive the growth of the global epigenetics market. However, standardization concerns over epigenetic-based diagnostics and lack of skilled professionals in this field restrict market growth. Nonetheless, rise in awareness regarding epigenetics in emerging economies would create lucrative opportunities for new market players in the near future.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/846 

Instruments in epigenetics are projected to grow at the fastest rate

Based on product, the instruments segment is expected to grow at the fastest CAGR of 14.9% during the forecast period, supplemented by the increasing use of instruments in the analytical and life-science industry. However, the kits & assays segment occupied more than one-third of the global market in 2016 and is expected to continue its dominance throughout 2023.

Oncology to remain the dominant segment through 2023

By application, the oncology segment is expected to garner almost two-thirds of the global market from 2017 to 2023, owing to the growing trend of biomarker research and the rise in the development of anticancer therapies. However, the non-oncology segment is projected to grow at the fastest rate during the forecast period, owing to the effectiveness of epigenetic therapies in treating metabolic, inflammatory, and cardiovascular diseases.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/846 

Academic & government research institutes are expected to dominate the market

Based on end user, academic & government research institutes is anticipated to remain the dominant segment throughout the forecast period owing to rise in demand for extraction services, library preparation, methylation services, and clinical grade-targeted sequencing among researchers and scientists. However, the biotechnology companies segment is expected to grow at the fastest CAGR of 13.7% from 2017 to 2023.

Asia-Pacific to encounter the highest growth in the near future

As the markets in developed countries are almost saturated, Asia-Pacific is projected to provide major opportunities to venture capitalists and investors throughout the forecast period. The region is expected to grow at the highest CAGR of 14.8%, driven by significant developments by China and Japan towards incorporating new technologies in healthcare.

Key market players

The key players analyzed in the report include Abcam plc., Illumina, QIAGEN N.V., Merck & Co., New England Biolabs, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., Active Motif. Diagenode, Inc., and Zymo Research Corporation. They have adopted different strategies including collaborations, joint ventures, partnerships, expansions, mergers & acquisitions, and others to gain a strong position in the industry.

Access KNOWLEDGE TREE (Premium on-demand, subscription-based pricing model) at: https://www.alliedmarketresearch.com/knowledgetree

Knowledge tree is a cloud-based intelligence platform that offers more than 2,000 selective, off-the-shelf reports on niche markets to enable our clients gain deep insights on the latest trends, dynamic technologies, and emerging application areas.

Similar Reports:

RNA Sequencing Market

Small Animal Imaging (In-Vivo) Market

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): 
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
[email protected] 

Web: https://www.alliedmarketresearch.com

SOURCE Allied Market Research

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED